In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

Biosimilar natalizumab (Tyruko) is approved by EMA, US FDA, MHRA etc. and article is intended only for the HCP audience in ...

Injectable medications for multiple sclerosis (MS) are known as disease-modifying therapies (DMTs). This means they work by slowing or changing the progression of the condition. These are ...

Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care ...

People with multiple sclerosis appear to have higher rates of thyroid problems than the general population. The link isn’t clear, but shared pathways and MS medication side effects may play a role. MS ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating multiple sclerosis.

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...